(Q47790307)

English

Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.

scientific article published on 8 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

Carmen E Gómez

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

Mariano Esteban

5

object named as

Mariano Esteban

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

José B Proal-Nájera

2

object named as

José L Nájera

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

author name string

Raquel Sánchez

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

Victoria Jiménez

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

language of work or name

0 references

publication date

8 April 2009

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

27

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

3165-3174

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

24

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

TNF/TNFR family members in costimulation of T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

The molecular architecture of the TNF superfamily

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

CD40/CD154 interactions at the interface of tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Apoptosis-inducing membrane vesicles. A novel agent with unique properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

CD40 ligand has potent antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Structural characteristics of CD40 ligand that determine biological function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Targeting with bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Quantification of antigen specific CD8+ T cells using an ELISPOT assay.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

HIV/AIDS vaccines: 2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Recombinant poxviruses as mucosal vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Cooperation between CD4+ and CD8+ T cells: when, where, and how.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

DNA vaccines: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

DNA vaccines against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

DNA vaccines against human immunodeficiency virus type 1 in the past decade

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

DNA vaccines: immunology, application, and optimization*

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.049

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.03.049

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446187

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47790307&oldid=1743024532"